Multimodal Treatment of Recurrent Colorectal Cancer

Introduction: Recurrent disease following colorectal cancer surgery will occur in about 30-50% of patients when considering both locoregional relapse and distant metastasis. For patients with rectal cancer, preoperative chemoradiotherapy followed by TME can provide durable 10-years overall survival (OS) of 58% and recurrence-free survival (RFS) of 62%. Background: Despite optimal treatment with neoadjuvant therapy and a complete TME, some rectal cancers still recur locally. Over the last two decades, the rates of local recurrence have been reduced. Patients and Methods: To identify the optimal treatment strategy patients can be divided into four clinical groups: resectable disease, potentially resectable, non-resectable with or without inten-